Lucence Diagnostics is creating liquid biopsies and blood tests that can be used to improve cancer detection. The earliest signs of cancer are subtle which has made early detection a challenge. Lucence is solving this problem by building sensitive blood-testing technologies that profile cancer both accurately and affordably. This includes LiquidHALLMARK®, Lucence’s liquid biopsy test that uses a sensitive next-generation sequencing assay targeting both circulating DNA and RNA to profile a patient’s unique cancer.

Lucence Diagnostics

Development Scientist - US (1 Year Contract)

Clinical Genomics & Medical Affairs Specialist - US

Genetic Counsellor

Precision Medicine Intern

R&D Intern

Business Development Manager  - Thailand

Customer Experience Operations (Manager/ Director)

Lucence raises $20 million Series A for its non-invasive cancer screening technology - TechCrunch

Lucence Diagnostics opens new HQ and Lab in Singapore - BSA bureau

Cancer screening startup Lucence raises US$20m in funding led by IHH - The Business Times

Multi-cancer early detection (MCED) in circulating tumor DNA (ctDNA) using an ultrasensitive mutation-based amplicon next-generation sequencing (NGS) assay

Lucence launches new cancer detection blood test - Agency for Science, Technology and Research (A*STAR)


              Triple whammy: Shocked by diagnoses of lung, liver and prostate cancers
            

Big thanks to SGInnovate for this great video about what we do at Lucence -making cancer detection better and faster. Together we're making a difference! 💪✨

Lucence Diagnostics to Develop AI Tools for Liver Cancer Treatment - Imaging Technology News


                Mayo Clinic Laboratories and Lucence announce strategic collaboration to enhance cancer testing services - Insights
              


              Lucence Secures MolDX Approval for LiquidHALLMARK® ctDNA and ctRNA Liquid Biopsy Test to Advance Non-Invasive Cancer Diagnostics | Lucence
            

Multi-cancer early detection (MCED) in circulating tumor DNA (ctDNA) using an ultrasensitive mutation-based amplicon next-generation sequencing (NGS) assay.

MEDx (Suzhou) and Lucence Partner to Co-Develop Cutting-Edge Cancer-Care Tests - Business Wire

iGenetic, Lucence Diagnostics team up to launch Liquid Biopsy Test in India - Elets

Dr Tan Min-Han’s start-up Lucence offering targeted cancer tests - The Edge Malaysia

Breast cancer is a challenging disease, and even more so for African women, who represent a neglected population.

In a world where optimal cancer care means identification of the right targets, so that drugs are useful and not futile, women of African ancestry typically have less access to both investigations and treatments.

It is thus critical to get things right to ensure diversity of cancer care. 

AMBER-01 is the first comprehensive precision oncology study in Africa, where women with breast cancer receive both combined tissue and liquid profiling.

Key findings: 

● Ghanaian women with metastatic breast cancer have a diverse range of actionable alterations, treatable with the right drugs.

● Liquid biopsy succeeded in delivering useful molecular sequencing results in 100% of Ghanaian women, compared to traditional tissue sampling for only 30% of women.  

We're proud to collaborate with Yemaachi Biotech and Cape Coast Teaching Hospital on this meaningful effort to bring better care to women of African ancestry!

Physicians

We're grateful to receive NHIC’s Rising Star Healthcare Innovation Tribute! 

This recognition is made possible by our strong Public-Private Partnerships (PPPs) with National Cancer Centre Singapore, National University Hospital, Singapore General Hospital, Tan Tock Seng Hospital, and DxD Hub - Diagnostics Development Hub. Your support inspires us to keep working hard to improve healthcare for everyone.

Congratulations to Biobot Surgical, Doctor Anywhere, and Mirxes on their outstanding achievements, and a big thank you to National Health Innovation Centre (NHIC) for a decade of fostering innovation and making meaningful change in healthcare. 

Here’s to many more years of collaboration and making a difference together! 🎉

Excited that our ctRNA and ctDNA liquid biopsy study has been selected as a Top 10 lung cancer study at #ASCO25 by OncoAlert!

Join the oral presentation at 8:00–9:30 AM CDT on June 2, 2025  https://lnkd.in/ghbWfKNM

A single urine test to detect bladder, kidney and prostate cancer - excited to be working with Singapore General Hospital and DxD Hub - Diagnostics Development Hub to make early detection simpler and smarter!

We’re thrilled to share that Lucence presented at the UBS Disruptive Technology CEO Summit 2024 in Hong Kong today! 

Our CEO, Min-Han Tan spoke on "Transforming Health: Multi-Cancer Screening in Blood", highlighting our mission to advance early cancer detection with LucenceINSIGHT™ for 50 cancers.

This summit brings together innovators, and at Lucence, we’re proud to contribute with our liquid biopsy technology for earlier, more accurate cancer detection.

A big thank you to UBS for this platform and to our Hong Kong partners, Gleneagles Hospital Hong Kong and Humansa, for your incredible support. Together, we’re building a future where earlier cancer detection saves more lives. 

Join Lucence at ESMO Asia 2024 in Singapore to learn more about multi-cancer screening!

Our CEO, Min-Han Tan will be speaking at a session on how technology enables Multi-Cancer Early Detection (MCED) liquid biopsies.

When: Saturday, 7 December 2024, 2:30 PM – 4:00 PM
Where: Suntec City, Room 324

Do join us to hear how MCED is shaping the future of healthcare!

Clinical utility of circulating tumor RNA (ctRNA) in a combined circulating tumor DNA (ctDNA) and ctRNA next-generation sequencing (NGS) pan-cancer liquid biopsy assay

Initial experience in a real-world Asian cohort with a circulating tumor DNA (ctDNA) mutation-based multi-cancer early detection (MCED) assay

Join Lucence at #ASCO25 as we present new data on our combined ctDNA and ctRNA liquid biopsy assay for cancer detection and monitoring!

🧬 Rapid Oral Presentation
Abstract #3016
Title: Clinical utility of circulating tumor RNA (ctRNA) in a combined circulating tumor DNA (ctDNA) and ctRNA next-generation sequencing (NGS) pan-cancer liquid biopsy assay
https://lnkd.in/ghbWfKNM 
Presenter: Dr Daniel Chan
When: June 2, 8:00–9:30 AM CDT
Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
 
📌 Poster Presentation
Abstract #3062
Title: Clinical outcomes of a prospective multicenter study evaluating a combined circulating tumor DNA (ctDNA) and RNA (ctRNA) liquid biopsy assay in metastatic non-small cell lung cancer (NSCLC)
https://lnkd.in/gDhiWGc9
Presenter: Prof GILBERTO de lima LOPES Junior
When: June 2, 1:30–4:30 PM CDT (Poster Board #377)
Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Contact us at asco25@lucence.com to meet or for collaboration!

Tests

We are pleased to introduce Rapid TissueMARK™ test in collaboration with Lucence in India. This tissue-based genomic test delivers high-resolution mutation profiling for solid tumors — supporting diagnosis and treatment planning.

#AgilusDiagnostics 


                Liquid Biopsy Enables Precision Cancer Care: Bill Morice, M.D., Ph.D. - Insights
              

We're incredibly grateful to Deputy Prime Minister Gan Kim Yong for the highlight and visit to our Singapore laboratory! A real honor to share how our liquid biopsy technology allows patients to live longer and better.

Complete mutation concordance with amplicon-based NGS between peripheral blood and bone marrow at 0.5% VAF threshold


              Lucence and Diagnostics Development Hub (DxD Hub) Collaborate on Expanding Multi-Cancer Early Detection Testing to Alternative Sample Types; Study Recruitment Starting In Q42024 | Lucence
            

IHH invests in Singapore-based Lucence Diagnostics - The Edge Malaysia

Medical innovation invented in Singapore - now helping to fight cancer for patients in the United States and worldwide!

So much gratitude to Enterprise Singapore for their steadfast support on this journey. 

We're hiring for roles in Singapore, USA and Hong Kong. Join us on the mission to scale up worldwide and help overcome cancer together!

Link: https://lnkd.in/gUrwNDsF

Real-world experience of an Asian pan-cancer combined DNA/RNA next generation sequencing (NGS) tissue biopsy assay

Thankful to be collaborating with Mayo! Learn more about LiquidHALLMARK at www.lucence.com

Cancer is a global challenge, with close to 1 million deaths reported in India annually.

We’re glad to announce a collaboration with Agilus Diagnostics to contribute to India's cancer care.

For the first time, Indian cancer patients and physicians can now access LiquidHALLMARK® ctDNA and ctRNA to better personalize cancer treatment. 

LiquidHALLMARK® is the only such #liquidbiopsy test fully covered by US Medicare.

Together, we can do better!

Learn more: https://lnkd.in/d-YwBp5C

Lucence launches first molecular test to distinguish breast tumours - BioSpectrum Asia

Singapore Diagnostics, Lucence partner to market cancer blood tests in Philippines - BioSpectrum Asia

These 5 startups came on top in the first Slingshot@Switch competition - Tech in Asia

Temasek unit-backed cancer testing firm Lucence to set up Hong Kong lab - South China Morning Post

Multi-Cancer Screening

Lucence Diagnostics opens new HQ and Lab in Singapore - BioSpectrum Asia

Companies recognised for innovations in fight against Covid-19 - The Straits Times

Lunch With Sumiko: Tan Min-Han fights cancer with a single draw of blood - The Straits Times

Dr Tan Min-Han's start-up Lucence offering targeted cancer tests - The Edge Singapore


              Lucence Announces Expanded Access for LiquidHALLMARK® Liquid Biopsy Test Through Participation Across Regence Plans | Lucence
            

Clinical outcomes of a prospective multicenter study evaluating a combined circulating tumor DNA (ctDNA) and RNA (ctRNA) liquid biopsy assay in metastatic non-small cell lung cancer (NSCLC)

Lucence Diagnostics

Business:

About: